The Clinical Spectrum of Autoimmune-Mediated Neurological Diseases in Patients Presenting to a Tertiary Care Hospital in Rawalpindi: The Clinical Spectrum of Autoimmune-Mediated Neurological Diseases in Patients

Mahwish Mustafa; Wasim Wali Muhammad; Hameed Ur Rehman; Atta Rasool; Fiza Wali; Fizza Khurram

doi:10.54393/pjhs.v7i3.3679

Authors

Mahwish Mustafa Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Wasim Wali Muhammad Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Hameed Ur Rehman Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Atta Rasool Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Fiza Wali Ripha International Hospital, Rawalpindi, Pakistan
Fizza Khurram Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v7i3.3679

Keywords:

Autoimmune Diseases, Neurological Manifestations, Autoantibodies, Clinical Spectrum

Abstract

Autoimmune-mediated neurological diseases (AMNDs) affect the central and peripheral nervous systems through inflammation and demyelination, leading to diverse neurological dysfunctions. Their heterogeneous clinical presentations complicate diagnosis, and epidemiological data in adult Pakistani populations remain scarce. Objectives: To determine the frequencies of different AMNDs among adult patients presenting to a tertiary care hospital in Rawalpindi. Methods: This cross-sectional study was conducted at the Department of Neurology, Pak Emirates Military Hospital, Rawalpindi, from 1^st April to 20^th September 2025, including 177 adult patients consecutively presenting with neurological symptoms suggestive of autoimmune etiology. The diagnosis was made on the basis of clinical manifestations supported by MRI, cerebrospinal fluid analysis, and autoantibodies. The analysis was performed using SPSS version 27.0. Results: The mean age of the patients was 47.9 ± 11.4 years. The majority of patients were female 108 (61%). Multiple Sclerosis was the most frequent diagnosis (27.1%), followed by autoimmune encephalitis (20.3%), Guillain-Barré syndrome (16.4%), myasthenia gravis (13.6%), and neuromyelitis optica spectrum disorder (10.7%). Anti-ganglioside antibodies showed the highest seropositivity (12.4%), while MRI and CSF abnormalities were observed in 33.9% and 38% of patients, respectively. Significant associations were found between disease type and age (p=0.018), gender (p=0.006), residence (p=0.041), family history (p=0.032), and symptom duration (p=0.014). Conclusions: Multiple Sclerosis, autoimmune encephalitis, and Guillain-Barré syndrome are the most prevalent AMNDs in this population, with distinct demographic patterns and variable diagnostic findings. Early recognition and integrated diagnostic approaches are essential to improve patient outcomes.

References

Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Frontiers in Neurology. 2021 Apr; 12: 664664. doi: 10.3389/fneur.2021.664664. DOI: https://doi.org/10.3389/fneur.2021.664664

Hsieh PC and Wu YR. Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders. Journal of Movement Disorders. 2022 May; 15(2): 95. doi: 10.14802/jmd.21077. DOI: https://doi.org/10.14802/jmd.21077

Nitsch S and Höftberger R. What We’ve Learnt About Autoimmune Neurological Diseases from Neuropathology. Revue Neurologique. 2024 Nov; 180(9): 908-15. doi: 10.1016/j.neurol.2024.08.009. DOI: https://doi.org/10.1016/j.neurol.2024.08.009

Constantinescu C and Gran B. The Essential Role of T Cells in Multiple Sclerosis: A Reappraisal. Biomedical Journal. 2014 Mar; 37(2): 34. doi: 10.4103/2319-4170.128746. DOI: https://doi.org/10.4103/2319-4170.128746

Huang YQ and Xiong H. Anti-NMDA Receptor Encephalitis: A Review of Mechanistic Studies. International Journal of Physiology, Pathophysiology and Pharmacology. 2021 Feb; 13(1): 1.

Shastri A, Al Aiyan A, Kishore U, Farrugia ME. Immune-Mediated Neuropathies: Pathophysiology and Management. International Journal of Molecular Sciences. 2023 Apr; 24(8): 7288. doi: 0.3390/ijms24087288. DOI: https://doi.org/10.3390/ijms24087288

Sepúlveda M, Sola-Valls N, Escudero D, Rojc B, Barón M, Hernández-Echebarría L et al. Clinical Profile of Patients with Paraneoplastic Neuromyelitis Optica Spectrum Disorder and Aquaporin-4 Antibodies. Multiple Sclerosis Journal. 2018 Nov; 24(13): 1753-9. doi: 10.1177/1352458517731914. DOI: https://doi.org/10.1177/1352458517731914

Hiesgen J and Schutte CM. Autoimmune Encephalitis: Epidemiology, Pathophysiology and Clinical Spectrum (Part 1). South African Medical Journal. 2023; 113(3): 116-21. doi: 10.7196/SAMJ.2023.v113i3.780. DOI: https://doi.org/10.7196/SAMJ.2023.v113i3.780

Scott EM, Shin M, Banati RB, Brown DA, Koethe D, Leweke FM et al. Neuroimmune-Mediated Neuropsychiatric Syndromes: Perspectives for Standardised Diagnostics and Personalised Care. Research Directions: Depression. 2024 Jan; 1: e25. doi: 10.1017/dep.2024.5. DOI: https://doi.org/10.1017/dep.2024.5

Jha S, Netravathi M, Holla VV, Kamble N, Mahadevan A, Pal PK. Movement Disorders in Autoimmune Encephalitis: Clinical Spectrum, Prognosis, and Outcomes from an Indian Cohort. Annals of Movement Disorders. 2024 Sep; 7(3): 189-95. doi: 0.4103/aomd.aomd_44_24. DOI: https://doi.org/10.4103/aomd.aomd_44_24

Smets I and Titulaer MJ. Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics. 2022 Apr; 19(3): 823-31. doi: 10.1007/s13311-021-01178-4. DOI: https://doi.org/10.1007/s13311-021-01178-4

Lubarski K, Mania A, Michalak S, Osztynowicz K, Mazur-Melewska K, Figlerowicz M. The Clinical Spectrum of Autoimmune-Mediated Neurological Diseases in Paediatric Population. Brain Sciences. 2022 Apr; 12(5): 584. doi: 10.3390/brainsci12050584. DOI: https://doi.org/10.3390/brainsci12050584

Kishk NA, Abdelfattah W, Shalaby NM, Shehata HS, Hassan A, Hegazy MI et al. The aquaporin4-IgG Status and How It Affects the Clinical Features and Treatment Response in NMOSD patients in Egypt. BioMed Central Neurology. 2021 Feb; 21(1): 53. doi: 10.1186/s12883-021-02083-1. DOI: https://doi.org/10.1186/s12883-021-02083-1

Pascual-Goñi E, Caballero-Ávila M, Querol L. Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test. Neurology. 2024 Aug; 103(4): e209725. doi: 10.1212/WNL.0000000000209725. DOI: https://doi.org/10.1212/WNL.0000000000209725

Rajput HM, Hassan M, Badshah M. Clinical and Radiological Profile of Neuromyelitis Optica Spectrum Disorders in A Pakistani Cohort. Multiple Sclerosis and Related Disorders. 2023 Jun; 74: 104656. doi: 10.1016/j.msard.2023.104656. DOI: https://doi.org/10.1016/j.msard.2023.104656

Dsouza D, John SK, Nadig R, Bhardwaj S, Sarma GR, Badachi S et al. Inpatient Burden of Neurological Disorders: A Route Map for Allocation of Resources and Postgraduate Training. Cureus. 2023 Dec; 15(12). DOI: https://doi.org/10.7759/cureus.51311

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. The Lancet Neurology. 2018 Feb; 17(2): 162-73. doi: 10.1016/S1474-4422(17)30470-2. DOI: https://doi.org/10.1016/S1474-4422(17)30470-2

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. 2015 Jul; 85(2): 177-89. doi: 10.1212/WNL.0000000000001729. DOI: https://doi.org/10.1212/WNL.0000000000001729

Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain–Barré Syndrome: Pathogenesis, Diagnosis, Treatment and Prognosis. Nature Reviews Neurology. 2014 Aug; 10(8): 469-82. doi: 10.1038/nrneurol.2014.121. DOI: https://doi.org/10.1038/nrneurol.2014.121

Aslan D, Bourabia S, Kowall B, Straukiene A, Jendretzky KF, Konen FF et al. The Impact of Autoimmune Comorbidities on Multiple Sclerosis Progression: Insights from a Longitudinal Single-Center Study. Journal of Neurology. 2025 Sep; 272(9): 607. doi: 10.1007/s00415-025-13351-2. DOI: https://doi.org/10.1007/s00415-025-13351-2

Holstiege JU, Steffen A, Goffrier B, Bätzing J. Epidemiology of Multiple Sclerosis – A Population-Based, Germany-Wide Study. 2017.

Di Liberto G, Uginet M, Lalive PH, Du Pasquier R. The Diagnostic Challenge of Autoimmune Encephalitis. Revue Medicale Suisse. 2024 Apr; 20(871): 822-7. doi: 10.53738/REVMED.2024.20.871.822. DOI: https://doi.org/10.53738/REVMED.2024.20.871.822

Mozafari P, Zehra S, Athuldoraarachchi DC, Mohammad M, Vaddempudi TC. Neuroimmunology of Autoimmune Encephalitis: From Antibody-Mediated Pathogenesis to Multidisciplinary Care. Junior Researchers. 2025 Sep; 3(5): 23-31. doi: 10.52340/jr.2025.03.05.03. DOI: https://doi.org/10.52340/jr.2025.03.05.03

Rajabally Z, Spencer L, Mistry N, Rajabally YA. Epidemiology, Presentation, Management and Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy in Birmingham, UK: The Impact of Ethnicity. Journal of the Peripheral Nervous System. 2025 Dec; 30(4): e70065. doi: 10.1111/jns.70065. DOI: https://doi.org/10.1111/jns.70065

Ajdacic-Gross V, Steinemann N, Horváth G, Rodgers S, Kaufmann M, Xu Y et al. Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors. Frontiers in Neurology. 2021 Jul; 12: 693440. doi: 10.3389/fneur.2021.693440. DOI: https://doi.org/10.3389/fneur.2021.693440

Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune Diseases Prior to the Diagnosis of Multiple Sclerosis: A Population-Based Case-Control Study. Multiple Sclerosis Journal. 2010 Jul; 16(7): 855-61. doi: 10.1177/1352458510369146. DOI: https://doi.org/10.1177/1352458510369146

Chang T. Navigating the Diagnostic and Therapeutic Complexities of Autoimmune Encephalitis. Sri Lanka Journal of Neurology. 2023 Dec; 10(2). doi: 10.4038/sljon.v10i2.155. DOI: https://doi.org/10.4038/sljon.v10i2.155

Rukmangadachar LA, Azevedo CJ. Neuroimaging Modalities in Neuroimmunology. Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases. 2021 Mar: 29-42. doi: 10.1007/978-3-030-61883-4_3. DOI: https://doi.org/10.1007/978-3-030-61883-4_3

Dos Passos GR, Adoni T, Mendes MF, Sato DK. Reshaping Neuroimmunology: Diagnosis and Treatment in the Era of Precision Medicine. Arquivos De Neuro-Psiquiatria. 2023 Dec; 81(12): 1125-33. doi: 10.1055/s-0043-1777752. DOI: https://doi.org/10.1055/s-0043-1777752

Cortés‐Vicente E, Borsi AJ, Gary C, Noel WG, Lee JM, Karmous W, Zhang Q, Gandhi KH, Batista AE, DeCourcy JJ, Barlow SG. The impact of diagnosis delay on European patients with generalised myasthenia gravis. Annals of Clinical and Translational Neurology. 2024 Sep;11(9):2254-67. doi: 10.1002/acn3.52122. DOI: https://doi.org/10.1002/acn3.52122

Aires A, Barros A, Machado C, Fitas D, Cação G, Pedrosa R et al. Diagnostic Delay of Multiple Sclerosis in a Portuguese Population. Acta Medica Portuguesa. 2019 Apr; 32(4): 289-94. doi: 10.20344/amp.11187. DOI: https://doi.org/10.20344/amp.11187